These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 659883)

  • 1. In situ lymphoid cells of mouse mammary tumors. III. In vitro stimulation of tumor cell survival by lymphoid cells separated from mammary tumors.
    Blazar BA; Miller FR; Heppner GH
    J Immunol; 1978 Jun; 120(6):1887-91. PubMed ID: 659883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ lymphoid cells of mouse mammary tumors. IV. Comparison of functional activity of lymphoid cells separated from mammary tumors to that of spleen and lymph node cells of tumor-sensitized mice.
    Ruppert B; Blazar B; Medina D; Heppner G
    J Immunol; 1979 Jun; 122(6):2180-3. PubMed ID: 448122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ lymphoid cells of mouse mammary tumors. II. The characterization of lymphoid cells separated from mouse mammary tumors.
    Blazer BA; Heppner GH
    J Immunol; 1978 Jun; 120(6):1881-6. PubMed ID: 659882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ lymphoid cells of mouse mammary tumors. I. Development and evaluation of a method for the separation of lymphoid cells from mouse mammary tumors.
    Blazar BA; Heppner GH
    J Immunol; 1978 Jun; 120(6):1876-80. PubMed ID: 659881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of lymphoid cells separated from mammary tumors in blastogenesis and Winn assays.
    Blazar BA; Laing CA; Miller FR; Heppner GH
    J Natl Cancer Inst; 1980 Aug; 65(2):405-10. PubMed ID: 6931258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microcytotoxicity assay of immune responses to non-mammary tumor virus-induced, preneoplastic, and neoplastic mammary lesions in BALB/c mice.
    Heppner GH; Kopp JS; Medina D
    Cancer Res; 1976 Feb; 36(2 pt 2):753-8. PubMed ID: 1253160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cytotoxic effector cells in the mouse mammary tumor system.
    Lane MA; Roubinian J; Slomich M; Trefts P; Blair PB
    J Immunol; 1975 Jan; 114(1 Pt 1):24-9. PubMed ID: 46242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro detection of immune responses to MTV-induced mammary tumors: qualitative differences in response detected by time studies.
    Blair PB; Lane MA
    J Immunol; 1975 Jan; 114(1 Pt 1):17-23. PubMed ID: 163276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of factors in sera of different mice that affect MTV-induced mammary tumor cells.
    Blair PB; Lane MA; Mar P
    J Immunol; 1976 Mar; 116(3):610-4. PubMed ID: 176267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependence of initiation of an innocent bystander cytotoxicity reaction on the association of viral antigens and tumor cell membranes in mice.
    Lopez DM; Lopez PF; Parks WP; Paul RD
    J Natl Cancer Inst; 1986 May; 76(5):923-31. PubMed ID: 2871214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of immune mechanisms against mammary tumors by incomplete T cell depletion.
    Roubinian JR; Lane MA; Slomich M; Blair PB
    J Immunol; 1976 Nov; 117(5 Pt.2):1767-73. PubMed ID: 186535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subset of spleen lymphocytes from BALB/cCrgl mice stimulated by mouse mammary tumor virus.
    Lopez DM; Charyulu V; Sigel MM
    Cancer Res; 1981 Mar; 41(3):813-8. PubMed ID: 6257384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separation of populations of sensitized lymphoid cells into fractions inhibiting and fractions enhancing syngeneic tumor growth in vivo.
    Small M; Trainin N
    J Immunol; 1976 Jul; 117(1):292-7. PubMed ID: 932428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophages of mouse mammary tumors. II. Differential distribution of macrophages from metastatic and nonmetastatic tumors.
    Mahoney KH; Fulton AM; Heppner GH
    J Immunol; 1983 Oct; 131(4):2079-85. PubMed ID: 6311907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of complement receptor-bearing cells in the spleens of tumor-bearing mice.
    Epstein RS; Lopez DM; Sigel MM; Ross GD
    J Immunol; 1978 Oct; 121(4):1524-7. PubMed ID: 308966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice.
    Buessow SC; Paul RD; Lopez DM
    J Natl Cancer Inst; 1984 Jul; 73(1):249-55. PubMed ID: 6610791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific stimulatory and cytotoxic effects of lymphocytes sensitized in vitro to either alloantigens or tumor antigens.
    Kall MA; Hellström I
    J Immunol; 1975 Mar; 114(3):1083-8. PubMed ID: 1112984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.